ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Principal Scientist at Generate:Biomedicines - ApplyBlast

Principal Scientist

Generate:Biomedicines

4 days ago

4.0 on Glassdoor

Somerville, Massachusetts, United States

Onsite

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Generate is seeking an accomplished Principal Scientist to lead Target Binding efforts within the Protein Analytics & Biophysics department. This role involves providing scientific and strategic leadership for protein-protein interaction and target-binding measurements across multiple biotherapeutic programs. The position combines hands-on technical expertise, novel technology development, and direct management of junior scientists and research associates.

Responsibilities

Lead target binding strategy and execution across multiple biotherapeutic programs
Design and optimize quantitative protein-protein interaction and cell-binding assays
Manage and mentor junior scientists and research associates

Skills

Qualifications

Ph.D. in biochemistry, biophysics, analytical chemistry, protein science, chemical biology, or a related discipline

About Generate:Biomedicines

generatebiomedicines.com

Headquarters

Somerville, Massachusetts, United States

Company Size

201-500 employees

View Profile

Generate:Biomedicines is a therapeutics company that combines machine learning, computational biology, and biological engineering to design and develop precision protein medicines and antibodies. Using generative AI and lab-driven engineering, the company builds targeted biologics and epitope-focused candidates, advancing a pipeline from discovery through clinical development. Its clinical-stage programs include GB-0895, a long‑acting anti‑TSLP antibody progressing to global Phase 3 studies, and the company has recently completed an initial public offering. Generate was incubated by Flagship Pioneering and emphasizes platform-driven discovery to accelerate novel biologic therapeutics.